VIROLOGIC es geht wieder los - 500 Beiträge pro Seite

[thommyboy]

Investor Relations - Press Releases

ViroLogic, Inc. (ticker: VLGC, exchange: NASDAQ) News Release - 9/3/2003

--------------------------------------------------------------------------------
ViroLogic Awarded NIH Grant to Develop Hepatitis C Virus Drug Resistance Test

SOUTH SAN FRANCISCO, Calif., Sep 3, 2003 /PRNewswire-FirstCall via COMTEX/ -- ViroLogic, Inc. (Nasdaq: VLGC) announced today that the Company has been awarded a grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the U.S. National Institutes of Health, to develop a Hepatitis C virus (HCV) drug susceptibility assay.

"This grant again reaffirms our leadership and expertise in anti-viral resistance research," said Bill Young, ViroLogic`s Chairman and Chief Executive Officer. "We believe it also demonstrates how our core competency in virology and assay development can be applied to HCV, a serious chronic viral disease."

Neil Parkin, Ph.D., Scientific Director, is the principal investigator of the project, which will focus on the development of rapid and sensitive assays to evaluate the susceptibility of HCV to investigational drugs that inhibit viral polymerase and protease that are both critical for HCV replication. These assays are expected to support the development and characterization of new anti-HCV drugs and the selection of optimal drug regimens for patients undertaking or failing anti-HCV drug therapy.

This latest grant follows the recent announcement of three other NIH grants to ViroLogic and brings the total grant awards announced this quarter to more than $4 million to be funded over three years.

About Hepatitis C

Hepatitis C is one of the most common chronic blood-borne infections in the United States. According to the U.S. Centers for Disease Control and Prevention, approximately 3.9 million Americans are infected with HCV. Currently, no vaccine is available to prevent new HCV infections. Left untreated, chronic HCV infection often leads to end stage liver disease and is the leading reason for liver transplantation in the United States. In contrast to the current treatment of chronic HCV infection, a combination of interferon and ribavirin, the next generations of anti-HCV drugs are designed to target specific viral proteins and directly block critical steps in the HCV replication cycle.

About ViroLogic

ViroLogic is a biotechnology company advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious viral diseases such as AIDS and hepatitis. The company`s products are designed to help doctors optimize treatment regimens that lead to better patient outcomes and reduced costs. ViroLogic`s technology is also being used by numerous biopharmaceutical companies to develop new and improved anti-viral therapeutics and vaccines targeted at emerging drug-resistant viruses. More information about the Company and its technology can be found on its web site at www.virologic.com.

Certain statements in this press release are forward-looking. These forward-looking statements are subject to risks and uncertainties and other factors, which may cause actual results to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These risks and uncertainties include, but are not limited to, the risks that the Company may not utilize the full amounts authorized under the grants, the risks that the programs funded by these grants may not achieve desired results, the risks that the Company`s products may not continue to perform in the same manner as indicated in the press release, whether licenses will be available to necessary intellectual property, whether the Company is able to maintain compliance with NASDAQ listing requirements, volatility in the price of its common stock, whether ViroLogic`s products will achieve market acceptance, the timing of pharmaceutical company clinical trials, whether payors will authorize reimbursement for its products, whether the Company will be able to expand its sales and marketing capabilities, whether the FDA or any other agency will decide to regulate its products or services, whether the Company encounters problems or delays in automating its processes, whether it successfully introduces new products, whether others introduce competitive products, whether intellectual property underlying its PhenoSense technology is adequate, whether it is able to build brand loyalty and expand revenues, and whether ViroLogic will be able to raise sufficient capital. For a discussion of other factors that may cause ViroLogic`s actual events to differ from those projected, please refer to the Company`s most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other subsequent filings with the Securities and Exchange Commission.

SOURCE ViroLogic, Inc.

Karen Wilson, CFO of ViroLogic, Inc., [phone], or
[e-mail]

http://www.virologic.com

[reno11]

Kann das jemand übersetzen?
Mein Schulenglisch reiht nicht aus.
Danke
Rene

[MaxLubin]

Return to Headlines Page
ViroLogic Says Co-Receptor Tropism And Replication Capacity Predict HIV Progression - Update [VLGC]
9/16/03 6:30:02 PM Tuesday evening, biotechnology company ViroLogic, Inc. (VLGC) announced that study results indicate that HIV Co-Receptor Tropism and Replication Capacity predict the clinical progression to AIDS.

The company stated that a retrospective study was performed on untreated or minimally-treated subjects enrolled from 1989-1990 and monitored for AIDS defining clinical endpoints through 1997.

ViroLogic stated that previous studies reveal a clear relationship between replication capacity and clinical progression to AIDS. It added that this follow-up study shows that Co-Receptor Tropism independently predicts immune system deterioration and HIV progression.

VLGC ended Tuesday’s regular trading session at $1.54, losing 2 cents.

[claudi34]

klingt ja gar nicht so schlecht diese nachricht.
und die aktie ist im gegensatz zu anderen mitbewerbern noch nicht gelaufen.
könnte was draus werden, wenn sich das marktumfeld bessert.
lg aus münchen

[thommyboy]

hi claudi,
darauf hoffe ich. hab mir schon ein paarmal gedacht "hätte man nicht aussteigen sollen" weil die immer intrayday bei meldungen hoch geht und dann wieder versackt, aber ich denke das potenzial nach unten ist geringer als das nach oben
gruss aus hessen
TOM

[claudi34]

mal schauen: ist aus meiner sicht eine längerfristige investition mit einem zeitfenster bis zu zwei jahren.
lg

[heikekarina]

[claudi34]

das baby wächst bereits...

[claudi34]

und das schneller als erwartet......

[Viva-los-Tioz]

Hallo zusammen,

ich bin auch schon eine Weile in Virolgic investiert und hoffe wir ernten bald die Früchte unserer Geduld.
Bei guten News kann es ganz schnell über 3 Dollar gehen.

Mfg
Viva

[Dolocher]

Dazu müssen wir aber erst einmal die 1,80 b.z.w. 2,0 schaffen,was sich bisher als recht schwierig erwiesen hat,wenn wir hier nicht genug Schwung mitbringen werden wir wohl ein weiteres mal abprallen.Das gute dabei ist,das man hier sehr gut traden kann
Mittelfristig kommen wir aber m.E. an den 3-5$ nicht vorbei

[Koenigstreuer]

Die Uno hat eine verzehnfachung der Aidshilfeprogramme angekündigt vielleicht fällt was ab!

[claudi34]

das gute an vir ist, dass ihre test-produkte in das segment "medizinische technik" fallen und deshalb nicht die lange zulassungs-prozedur der us-gesundheitsbehörde über sich ergehen lassen müssen.
lg

[Dolocher]

Wichtig für die Zukunft ist aber vor allem,DAS erst einmal einpaar neue Produkte an den Markt kommen,um(hoffentlich noch in diesem Jahr) schwarze Zahlen schreiben zu können,denn bisher ist die Pipeline noch etwas dürftig.Wenn die bisher noch in der letzten Testphase befindlichen Produkte zugelassen werden kann man auch von einer nachhaltigen Kurssteigerung ausgehen,bis dahin werden wir uns wohl weiter Stück für Stück und Prozent für Prozent in Richtung Norden vorarbeiten müssen.
Trotz alledem sehe ich VLGC zu Jahresende bei über 2$,womit die ersten 100% schon mal gesichert wären...

MfG

[Dolocher]

Morgen gibts Q3 Zahlen...hoffentlich gute!

[oasenfred]

Da musst Du wohl noch etwas warten...

ViroLogic Announces Third Quarter 2003 Earnings Conference Call
Wednesday October 22, 8:30 am ET
Tuesday, November 4, 2003 at 5:00 p.m. ET, 2:00 p.m. PT


SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct. 22, 2003--ViroLogic, Inc. (Nasdaq:VLGC - News) announced that it will hold a conference call on Tuesday, November 4, 2003 at 5:00 p.m. ET to discuss third quarter earnings results. The call will be hosted by Mr. Bill Young, Chairman & CEO of ViroLogic, Inc.
To participate in the teleconference please call [phone] fifteen minutes before the conference begins. International callers please dial [phone].

The call will also be webcast live at www.virologic.com. Please see web site for details.